Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00407745
Other study ID # A0081107
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date January 2007
Est. completion date February 2011

Study information

Verified date February 2012
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate if pregabalin relieves nerve pain associated with spinal cord injury compared to placebo (pill that contains no active medicine). This study will also evaluate the safety of pregabalin in this patient population.


Recruitment information / eligibility

Status Completed
Enrollment 220
Est. completion date February 2011
Est. primary completion date February 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects with nerve pain after Spinal cord injury (traumatic, diving, ischemic and after removal of benign tumors (except meningioma and fibromas) - Pain has to be chronic(continuous for at least 3 months or intermittent for at least 6 months - Pain score at least 4 in 4 of 7 days prior to receive treatment. Exclusion Criteria: - Pregabalin use in the last 60 days, prior intolerance to pregabalin - Creatinine clearance <60 mL/min. - White blood cell count <2500/mm3; neutrophil count <1500/mm3; platelet count <100 x 103/ mm3. - Abuse of drugs or alcohol - Unstable medial conditions - Clinically significant abnormal electrocardiogram (ECG). - Presence of severe pain associated with conditions other than spinal cord injury that could confound the assessment or self-evaluation of pain due to spinal cord injury.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
placebo
Placebo
pregabalin
Pregabalin capsules taken twice daily up to 17 weeks (150-600 mg/day)

Locations

Country Name City State
Chile Pfizer Investigational Site Vina del Mar V Region
China Pfizer Investigational Site Beijing Beijing
China Pfizer Investigational Site Beijing
China Pfizer Investigational Site Chengdu Sichuan
Colombia Pfizer Investigational Site Medellín Antioquia
Czechia Pfizer Investigational Site Brno
Czechia Pfizer Investigational Site Liberec 1
Czechia Pfizer Investigational Site Praha 5
Hong Kong Pfizer Investigational Site Hong Kong
India Pfizer Investigational Site Bangalore Karnataka
India Pfizer Investigational Site Bangalore Karnataka
India Pfizer Investigational Site Lucknow Uttar Pradesh
India Pfizer Investigational Site Mangalore Karnataka
India Pfizer Investigational Site New Delhi
India Pfizer Investigational Site Secunderabad Andhra Pradesh
Japan Pfizer Investigational Site Beppu Oita
Japan Pfizer Investigational Site Bibai Hokkaido
Japan Pfizer Investigational Site Chiba
Japan Pfizer Investigational Site Daisen Akita
Japan Pfizer Investigational Site Fukuyama Hiroshima
Japan Pfizer Investigational Site Hakodate Hokkaido
Japan Pfizer Investigational Site Hamamatsu Shizuoka
Japan Pfizer Investigational Site Hanyu Saitama
Japan Pfizer Investigational Site Higashiokitama-gun Yamagata
Japan Pfizer Investigational Site Iizuka Fukuoka
Japan Pfizer Investigational Site Kanuma Tochigi
Japan Pfizer Investigational Site Kashiwazaki Niigata
Japan Pfizer Investigational Site Kawasaki Kanagawa
Japan Pfizer Investigational Site Kikuchi-gun Kumamoto
Japan Pfizer Investigational Site Kitamoto Saitama
Japan Pfizer Investigational Site Kobe Hyogo
Japan Pfizer Investigational Site Kotoku Tokyo
Japan Pfizer Investigational Site Musashimurayama-shi Tokyo
Japan Pfizer Investigational Site Nagoya Aichi
Japan Pfizer Investigational Site Sapporo Hokkaido
Japan Pfizer Investigational Site Sasima-gun Ibaraki
Japan Pfizer Investigational Site Sendai Miyagi
Japan Pfizer Investigational Site Tokushima
Japan Pfizer Investigational Site Yamagata
Philippines Pfizer Investigational Site Cebu City
Philippines Pfizer Investigational Site Espana Manila
Philippines Pfizer Investigational Site Manila
Philippines Pfizer Investigational Site Quezon City
Russian Federation Pfizer Investigational Site Moscow
Russian Federation Pfizer Investigational Site St.Petersburg
United States Pfizer Investigational Site Bellevue Ohio
United States Pfizer Investigational Site Charleston West Virginia
United States Pfizer Investigational Site Charleston West Virginia
United States Pfizer Investigational Site Dallas Texas
United States Pfizer Investigational Site Detroit Michigan
United States Pfizer Investigational Site Fresno California
United States Pfizer Investigational Site Indianapolis Indiana
United States Pfizer Investigational Site Johnstown Pennsylvania
United States Pfizer Investigational Site Miami Florida
United States Pfizer Investigational Site Miami Florida
United States Pfizer Investigational Site Napa California
United States Pfizer Investigational Site New York New York
United States Pfizer Investigational Site Northridge California
United States Pfizer Investigational Site Orlando Florida
United States Pfizer Investigational Site Overland Park Kansas
United States Pfizer Investigational Site Pasadena California
United States Pfizer Investigational Site Philadelphia Pennsylvania
United States Pfizer Investigational Site Phoenix Arizona
United States Pfizer Investigational Site Phoenix Arizona
United States Pfizer Investigational Site Phoenix Arizona
United States Pfizer Investigational Site White Plains New York
United States Pfizer Investigational Site Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Countries where clinical trial is conducted

United States,  Chile,  China,  Colombia,  Czechia,  Hong Kong,  India,  Japan,  Philippines,  Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Other Change From Baseline in Weekly Mean Sleep Interference Score by Week Pain related sleep interference was assessed on an 11 point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered [unable to sleep due to pain]). Baseline, Week 1 through 16
Primary Duration Adjusted Average Change (DAAC) of Mean Pain Score DAAC was derived from participant's daily pain diary, where pain was measured on an 11-point Numerical Rating Scale (NRS-Pain)ranging from 0 (did not interfere with sleep) to 10 (completely interfered [unable to sleep due to pain]). The DAAC was calculated as the mean of all daily pain diary rating post baseline minus the baseline score then multiplied by the proportion of the planned study duration completed by the participant. Baseline, Week 16
Secondary Change From Baseline in Weekly Mean Pain Score Mean weekly score was calculated as the average of the available daily diary pain score values for the week. Pain score was measured on an 11-point numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain). Baseline, Week 16
Secondary Number of Participants With >=30% Reduction in Weekly Mean Pain Score From Baseline Mean weekly score was calculated as the average of the available daily diary pain score values for the week. Pain score was measured on an 11-point numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain). Baseline, Week 16
Secondary Number of Participants With Categorical Scores on the Patient Global Impression of Change (PGIC) (Full Scale) The PGIC is a participant-rated instrument measuring change in the participant's overall status on a 7-point scale: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. Baseline, Week 16
Secondary Change From Baseline in Weekly Mean Sleep Interference Score Pain-related sleep interference was assessed on an 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered [unable to sleep due to pain]). Baseline, Week 16
Secondary Change From Baseline in Weekly Mean Pain Score by Week Mean weekly score was calculated as the average of the available daily diary pain score values for the week. Pain score was measured on an 11-point numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain). Baseline, Week 1 through16
Secondary Number of Participants With >=50% Reduction in Weekly Mean Pain Score From Baseline Mean weekly score was calculated as the average of the available daily diary pain score values for the week. Pain score was measured on an 11-point numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain). Baseline, Week 16
Secondary Change From Baseline in Modified Brief Pain Inventory Interference Scale (10-Item) (mBPI-10) Total Score The Modified Brief Pain Inventory (mBPI-10) Interference Scale is a self administered questionnaire that assessed pain interference with functional activities over the past week. The items were measured on an 11 point scale, ranging from "does not interfere" (0) to "completely interferes" (10). A composite score, the pain interference index, was calculated by averaging the 10 items that comprised the scale. Baseline, Week 16
Secondary Change From Baseline in Quantitative Assessment of Neuropathic Pain (QANeP) - Static Mechanical Allodynia Participant rated pain scale. The pain produced by the applied stimulus (static mechanical allodynia - gentle constant mechanical pressure) was rated on an 11 point numerical rating scale (0=no pain, 10=worst possible pain). Baseline, Week 16
Secondary Change From Baseline in Quantitative Assessment of Neuropathic Pain (QANeP) - Dynamic Mechanical Allodynia Participant rated pain scale. The pain produced by the applied stimulus (dynamic mechanical allodynia - gentle stroking with foam brush) was rated on an 11 point numerical rating scale (0=no pain, 10=worst possible pain). Baseline, Week 16
Secondary Change From Baseline in Quantitative Assessment of Neuropathic Pain (QANeP)- Punctata Hyperalgesia Participant rated pain scale. The pain produced by the applied stimulus (Punctata hyperalgesia - pinprick) was rated on an 11 point numerical rating scale (0=no pain, 10=worst possible pain). Baseline, Week 16
Secondary Change From Baseline in Quantitative Assessment of Neuropathic Pain (QANeP)- Temporal Summation to Tactile Stimuli Participant rated pain scale. The pain produced by the applied stimulus (Temporal summation to tactile stimuli - repeated touching/tapping) was rated on an 11 point numerical rating scale (0=no pain, 10=worst possible pain). Baseline, Week 16
Secondary Change From Baseline in Quantitative Assessment of Neuropathic Pain (QANeP)- Cold Allodynia Participant rated pain scale. The pain produced by the applied stimulus (Cold allodynia - touch with cool metal rod 13-17 degrees celsius was rated on an 11 point numerical rating scale (0=no pain, 10=worst possible pain). Baseline, Week 16
Secondary Change From Baseline in Quantitative Assessment of Neuropathic Pain (QANeP)- Cold Hyperalgesia Subscales Participant rated pain scale. The pain produced by the applied stimulus (Cold hyperalgesia - touch with cold metal rod 4 degrees celsius) was rated on an 11 point numerical rating scale (0=no pain, 10=worst possible pain). Baseline, Week 16
Secondary Change From Baseline in Neuropathic Pain Symptom Inventory (NPSI) - 12 Items Total Intensity Score Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. Baseline, Week 16
Secondary Change From Baseline in Neuropathic Pain Symptom Inventory (NPSI) - Burning Spontaneous Pain Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. Baseline, Week 16
Secondary Change From Baseline in Neuropathic Pain Symptom Inventory (NPSI) - Pressing Spontaneous Pain Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. Baseline, Week 16
Secondary Change From Baseline in Neuropathic Pain Symptom Inventory (NPSI) - Paroxysmal Pain Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. Baseline, Week 16
Secondary Change From Baseline in Neuropathic Pain Symptom Inventory (NPSI) - Evoked Pain Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. Baseline, Week 16
Secondary Change From Baseline in Neuropathic Pain Symptom Inventory (NPSI) - Paresthesia/Dysesthesia Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. Baseline, Week 16
Secondary Change From Baseline in Neuropathic Pain Symptom Inventory (NPSI) - Individual Item (1, 2, 3, 5, 6, 8, 9, 10, 11, 12) Score Participant rated questionnaire used to evaluate different symptoms of neuropathic pain (dimensions: burning [superficial] spontaneous pain, pressing [deep] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia [P/D]). Includes 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. Questionnaire generates a score in each of the relevant dimensions and a total score of 0-100. Higher score indicates a greater intensity of pain. Baseline, Week 16
Secondary Number of Participants With Improved Duration of Brief Pain Attacks Based on NPSI - Duration (Item 4) NPSI - Temporal item which assesses the duration (number of hours during the last 24 hours) of spontaneous ongoing pain. Improved duration would be a decrease in the number of hours of spontaneous ongoing pain during the last 24 hours compared to baseline. Baseline, Week 16
Secondary Number of Participants With Improvement in the Number of Attacks Based on NPSI - Number of Attacks (Item 7) NPSI - Temporal item which assesses the paroxysmal pain (number of pain attacks during the last 24 hours). Improvement in the number of attacks would be a decrease in the number of paroxysms during the last 24 hours compared to baseline. Baseline, Week 16
Secondary Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS)- 9-Item Overall Sleep Problems Index Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. Baseline, Week 16
Secondary Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS) - Sleep Disturbance Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. Baseline, Week 16
Secondary Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS) - Sleep Adequacy Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. Baseline, Week 16
Secondary Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS) - Snoring Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. Baseline, Week 16
Secondary Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS) - Awaken Short of Breath or With a Headache Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. Baseline, Week 16
Secondary Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS) - Sleep Quantity Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. Baseline, Week 16
Secondary Change From Baseline in Medical Outcomes Study Sleep Scale (MOS-SS) - Somnolence Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. Baseline, Week 16
Secondary Number of Participants Having Optimal Sleep Based on Medical Outcomes Study Sleep Scale (MOS-SS) Participant rated questionnaire to assess sleep quality and quantity. Consists of a 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); 7 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath (SOB) or with a headache, somnolence adequacy, and sleep quantity. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range multiplied by 100); total score range = 0 to 100; higher score indicates greater intensity of attribute. Baseline, Week 16
Secondary Change From Baseline in Hospital and Anxiety Depression Scale (HADS) - Anxiety HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms. Baseline, Week 16
Secondary Change From Baseline in Hospital and Anxiety Depression Scale (HADS) - Depression HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms. Baseline, Week 16
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06321172 - Muscle and Bone Changes After 6 Months of FES Cycling N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05484557 - Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury N/A
Suspended NCT05542238 - The Effect of Acute Exercise on Cardiac Autonomic, Cerebrovascular, and Cognitive Function in Spinal Cord Injury N/A
Recruiting NCT05503316 - The Roll of Balance Confidence in Gait Rehabilitation in Persons With a Lesion of the Central Nervous System N/A
Not yet recruiting NCT05506657 - Early Intervention to Promote Return to Work for People With Spinal Cord Injury N/A
Recruiting NCT04105114 - Transformation of Paralysis to Stepping Early Phase 1
Recruiting NCT03680872 - Restoring Motor and Sensory Hand Function in Tetraplegia Using a Neural Bypass System N/A
Completed NCT04221373 - Exoskeletal-Assisted Walking in SCI Acute Inpatient Rehabilitation N/A
Completed NCT00116337 - Spinal Cord Stimulation to Restore Cough N/A
Completed NCT03898700 - Coaching for Caregivers of Children With Spinal Cord Injury N/A
Recruiting NCT04883463 - Neuromodulation to Improve Respiratory Function in Cervical Spinal Cord Injury N/A
Active, not recruiting NCT04881565 - Losing Balance to Prevent Falls After Spinal Cord Injury (RBT+FES) N/A
Completed NCT04864262 - Photovoice for Spinal Cord Injury to Prevent Falls N/A
Recruiting NCT04007380 - Psychosocial, Cognitive, and Behavioral Consequences of Sleep-disordered Breathing After SCI N/A
Active, not recruiting NCT04544761 - Resilience in Persons Following Spinal Cord Injury
Completed NCT03220451 - Use of Adhesive Elastic Taping for the Therapy of Medium/Severe Pressure Ulcers in Spinal Cord Injured Patients N/A
Terminated NCT03170557 - Randomized Comparative Trial for Persistent Pain in Spinal Cord Injury: Acupuncture vs Aspecific Needle Skin Stimulation N/A
Recruiting NCT04811235 - Optical Monitoring With Near-Infrared Spectroscopy for Spinal Cord Injury Trial N/A
Recruiting NCT04736849 - Epidural and Dorsal Root Stimulation in Humans With Spinal Cord Injury N/A